Document is current
Any future updates will be listed below
-
Authors
Navarro-Compán, Victoria https://orcid.org/0000-0002-4527-852X
Reveille, John D.
Rahman, Proton
Maldonado-Cocco, José A.
Magrey, Marina
Bolce, Rebecca
Panni, Tommaso
Kronbergs, Andris
Rudwaleit, Martin
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02696785 at ClinicalTrials.govnct02696798 at ClinicalTrials.govDocuments that mention this clinical trial
POS0918 EVALUATION OF SPINAL RADIOGRAPHIC PROGRESSION IN PATIENTS WITH RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS RECEIVING IXEKIZUMAB THERAPY OVER 2 YEARS
https://doi.org/10.1136/annrheumdis-2021-eular.1620
Does HLA-B27 Status Influence Ixekizumab Efficacy in Axial Spondyloarthritis? Results From the COAST-V, COAST-W, and COAST-X Trials
https://doi.org/10.1007/s40744-025-00810-5
THU0396 IMPACT OF IXEKIZUMAB ON WORK PRODUCTIVITY IN PATIENTS WITH ANKYLOSING SPONDYLITIS: RESULTS FROM THE COAST-V AND COAST-W TRIALS AT 52 WEEKS
https://doi.org/10.1136/annrheumdis-2020-eular.2053
AB0710 IXEKIZUMAB SIGNIFICANTLY IMPROVES SELF-REPORTED OVERALL HEALTH AS MEASURED BY SF-36 IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS/RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS NAIVE TO BIOLOGICAL THERAPY: 52 WEEK RESULTS OF A PHASE 3 TRIAL
https://doi.org/10.1136/annrheumdis-2019-eular.1612
OP0046 EFFECT OF IXEKIZUMAB TREATMENT ON MRI STRUCTURAL LESIONS IN THE SACROILIAC JOINTS OF PATIENTS WITH RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS; A POST-HOC ANALYSIS OF A PLACEBO AND ACTIVE CONTROLLED RCT
https://doi.org/10.1136/annrheumdis-2024-eular.602
Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W) (Results)
https://doi.org/10.1136/annrheumdis-2019-216118
Work productivity in patients with axial spondyloarthritis initiating biological or targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review and meta-analysis
https://doi.org/10.1136/rmdopen-2023-003468
OP0238 WORK PRODUCTIVITY AND ACTIVITY IMPAIRMENT AMONG PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS/RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS AND TREATED WITH IXEKIZUMAB FOR 16 WEEKS: RESULTS FROM COAST-V AND COAST-W
https://doi.org/10.1136/annrheumdis-2019-eular.1613
FRI0398 IXEKIZUMAB IS EFFECTIVE IN THE TREATMENT OF RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS REGARDLESS OF THE LEVEL OF C-REACTIVE PROTEIN OR MAGNETIC RESONANCE IMAGING SCORES: 16-WEEK DATA FROM COAST-V AND COAST-W
https://doi.org/10.1136/annrheumdis-2019-eular.1466
FRI0420 IXEKIZUMAB SIGNIFICANTLY IMPROVES SELF-REPORTED OVERALL HEALTH IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS/RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: SF-36 RESULTS OF TWO PHASE 3 TRIALS
https://doi.org/10.1136/annrheumdis-2019-eular.1237
Continuing versus withdrawing ixekizumab treatment in patients with axial spondyloarthritis who achieved remission: efficacy and safety results from a placebo-controlled, randomised withdrawal study (COAST-Y)
https://doi.org/10.1136/annrheumdis-2020-219717
POS0901 IXEKIZUMAB SHOWS A DISTINCT PATTERN OF PAIN IMPROVEMENT BEYOND INFLAMMATION IN RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS
https://doi.org/10.1136/annrheumdis-2021-eular.211
Test–retest reliability of outcome measures: data from three trials in radiographic and non-radiographic axial spondyloarthritis
https://doi.org/10.1136/rmdopen-2021-001839
Efficacy and safety of ixekizumab treatment in patients with axial spondyloarthritis: 2-year results from COAST
https://doi.org/10.1136/rmdopen-2021-002165
POS1118 DISCRIMINATING CAPACITY OF THE ASAS HEALTH INDEX IN PATIENTS TREATED WITH IXEKIZUMAB IN THE COAST PROGRAMME
https://doi.org/10.1136/annrheumdis-2023-eular.82
FRI0400 LONG-TERM SAFETY OF IXEKIZUMAB IN PATIENTS WITH RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS/ANKYLOSING SPONDYLITIS: AN INTEGRATED ANALYSIS OF COAST-V AND COAST-W
https://doi.org/10.1136/annrheumdis-2019-eular.1232
POS0909 IXEKIZUMAB IMPROVES SIGNS, SYMPTOMS AND QUALITY OF LIFE OF ANKYLOSING SPONDYLITIS IN PATIENTS IRRESPECTIVE OF HLA-B27 STATUS: POOLED RESULTS FROM THE COAST-V AND COAST-W TRIALS
https://doi.org/10.1136/annrheumdis-2021-eular.801
Baseline Characteristics and Treatment Response to Ixekizumab Categorised by Sex in Radiographic and Non-radiographic Axial Spondylarthritis Through 52 Weeks: Data from Three Phase III Randomised Controlled Trials
https://doi.org/10.1007/s12325-022-02132-2
POS0931 EFFICACY AND IMPROVEMENT IN PATIENT-REPORTED OUTCOMES AT WEEKS 16 AND 52 IN IXEKIZUMAB TREATED BIOLOGICAL NAÏVE PATIENTS WITH RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS ACHIEVING CLINICALLY IMPORTANT PAIN AT NIGHT REDUCTION AT WEEK 16: RESULTS FROM COAST-V TRIAL
https://doi.org/10.1136/annrheumdis-2022-eular.169
POS0908 EFFICACY OF IXEKIZUMAB THROUGH 52 WEEKS FOR IMPROVING PERIPHERAL JOINT INVOLVEMENT AMONG PATIENTS WITH RADIOGRAPHIC-AXIAL SPONDYLOARTHRITIS
https://doi.org/10.1136/annrheumdis-2021-eular.761
POS0957 EXTERNAL VALIDATION OF THE ALTERNATIVE ANKYLOSING SPONDYLITIS DISEASE ACTIVITY SCORE IN THREE PHASE-3 RCTs
https://doi.org/10.1136/annrheumdis-2022-eular.372
POS0915 SUSTAINABILITY OF IXEKIZUMAB RESPONSE AT THE INDIVIDUAL PATIENT LEVEL OVER TIME IN RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS
https://doi.org/10.1136/annrheumdis-2021-eular.1340
OP0034 IXEKIZUMAB IMPROVES SIGNS, SYMPTOMS, AND QUALITY OF LIFE IN PATIENTS WITH AXIAL SpA IRRESPECTIVE OF DISEASE DURATION: RESULTS FROM THE COAST-V, COAST-W AND COAST-X TRIALS
https://doi.org/10.1136/annrheumdis-2022-eular.164
AB0868 HOW DO EARLY DISEASE ACTIVITY AND EARLY CLINICAL RESPONSE ASSOCIATE WITH LONG-TERM OUTCOMES WITH IXEKIZUMAB IN RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS?
https://doi.org/10.1136/annrheumdis-2024-eular.623
Ixekizumab Improves Signs, Symptoms, and Quality of Life in Patients with Axial Spondyloarthritis Irrespective of Symptom Duration
https://doi.org/10.1007/s12325-025-03305-5
Incidence of infections in patients with psoriatic arthritis and axial spondyloarthritis treated with biological or targeted disease-modifying agents: a systematic review and meta-analysis of randomised controlled trials, open-label studies and observational studies
https://doi.org/10.1136/rmdopen-2023-003064
FRI0421 IXEKIZUMAB SIGNIFICANTLY REDUCED PAIN, INFLAMMATION, AND FATIGUE IN PATIENTS WITH RADIOGRAPHIC AXIAL SPONDYLARTHRITIS (R-AXSPA)/ANKYLOSING SPONDYLITIS (AS)
https://doi.org/10.1136/annrheumdis-2019-eular.1236
Early clinical response associates with long-term outcomes with ixekizumab in radiographic axial spondyloarthritis
https://doi.org/10.1136/rmdopen-2024-004429
Recapture and retreatment rates with ixekizumab after withdrawal of therapy in patients with axial spondyloarthritis: results at week 104 from a randomised placebo-controlled withdrawal study
https://doi.org/10.1136/ard-2022-222731
nct02757352 at ClinicalTrials.govDocuments that mention this clinical trial
POS0926 NORMALIZATION OF HIGH SENSITIVITY CRP VERSUS CLINICAL RESPONSE TO IXEKIZUMAB AT WEEK 16 IN PATIENTS WITH RADIOGRAPHIC & NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: RESULTS FROM THE COAST STUDIES
https://doi.org/10.1136/annrheumdis-2021-eular.2079
POS0918 EVALUATION OF SPINAL RADIOGRAPHIC PROGRESSION IN PATIENTS WITH RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS RECEIVING IXEKIZUMAB THERAPY OVER 2 YEARS
https://doi.org/10.1136/annrheumdis-2021-eular.1620
Does HLA-B27 Status Influence Ixekizumab Efficacy in Axial Spondyloarthritis? Results From the COAST-V, COAST-W, and COAST-X Trials
https://doi.org/10.1007/s40744-025-00810-5
THU0396 IMPACT OF IXEKIZUMAB ON WORK PRODUCTIVITY IN PATIENTS WITH ANKYLOSING SPONDYLITIS: RESULTS FROM THE COAST-V AND COAST-W TRIALS AT 52 WEEKS
https://doi.org/10.1136/annrheumdis-2020-eular.2053
Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W) (Results)
https://doi.org/10.1136/annrheumdis-2019-216118
Work productivity in patients with axial spondyloarthritis initiating biological or targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review and meta-analysis
https://doi.org/10.1136/rmdopen-2023-003468
AB1321 PSYCHOMETRIC PROPERTIES OF THE ASAS HEALTH INDEX IN PATIENTS WITH ACTIVE AS/RADIOGRAPHIC AXIAL SPA WHO HAVE PRIOR INADEQUATE RESPONSE/INTOLERANCE TO TNF INHIBITORS IN A PHASE 3 TRIAL
https://doi.org/10.1136/annrheumdis-2019-eular.1615
OP0238 WORK PRODUCTIVITY AND ACTIVITY IMPAIRMENT AMONG PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS/RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS AND TREATED WITH IXEKIZUMAB FOR 16 WEEKS: RESULTS FROM COAST-V AND COAST-W
https://doi.org/10.1136/annrheumdis-2019-eular.1613
FRI0398 IXEKIZUMAB IS EFFECTIVE IN THE TREATMENT OF RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS REGARDLESS OF THE LEVEL OF C-REACTIVE PROTEIN OR MAGNETIC RESONANCE IMAGING SCORES: 16-WEEK DATA FROM COAST-V AND COAST-W
https://doi.org/10.1136/annrheumdis-2019-eular.1466
FRI0420 IXEKIZUMAB SIGNIFICANTLY IMPROVES SELF-REPORTED OVERALL HEALTH IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS/RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: SF-36 RESULTS OF TWO PHASE 3 TRIALS
https://doi.org/10.1136/annrheumdis-2019-eular.1237
Continuing versus withdrawing ixekizumab treatment in patients with axial spondyloarthritis who achieved remission: efficacy and safety results from a placebo-controlled, randomised withdrawal study (COAST-Y)
https://doi.org/10.1136/annrheumdis-2020-219717
Efficacy and safety of ixekizumab treatment in patients with axial spondyloarthritis: 2-year results from COAST
https://doi.org/10.1136/rmdopen-2021-002165
POS1118 DISCRIMINATING CAPACITY OF THE ASAS HEALTH INDEX IN PATIENTS TREATED WITH IXEKIZUMAB IN THE COAST PROGRAMME
https://doi.org/10.1136/annrheumdis-2023-eular.82
FRI0400 LONG-TERM SAFETY OF IXEKIZUMAB IN PATIENTS WITH RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS/ANKYLOSING SPONDYLITIS: AN INTEGRATED ANALYSIS OF COAST-V AND COAST-W
https://doi.org/10.1136/annrheumdis-2019-eular.1232
POS0909 IXEKIZUMAB IMPROVES SIGNS, SYMPTOMS AND QUALITY OF LIFE OF ANKYLOSING SPONDYLITIS IN PATIENTS IRRESPECTIVE OF HLA-B27 STATUS: POOLED RESULTS FROM THE COAST-V AND COAST-W TRIALS
https://doi.org/10.1136/annrheumdis-2021-eular.801
Baseline Characteristics and Treatment Response to Ixekizumab Categorised by Sex in Radiographic and Non-radiographic Axial Spondylarthritis Through 52 Weeks: Data from Three Phase III Randomised Controlled Trials
https://doi.org/10.1007/s12325-022-02132-2
POS0908 EFFICACY OF IXEKIZUMAB THROUGH 52 WEEKS FOR IMPROVING PERIPHERAL JOINT INVOLVEMENT AMONG PATIENTS WITH RADIOGRAPHIC-AXIAL SPONDYLOARTHRITIS
https://doi.org/10.1136/annrheumdis-2021-eular.761
POS0957 EXTERNAL VALIDATION OF THE ALTERNATIVE ANKYLOSING SPONDYLITIS DISEASE ACTIVITY SCORE IN THREE PHASE-3 RCTs
https://doi.org/10.1136/annrheumdis-2022-eular.372
POS0915 SUSTAINABILITY OF IXEKIZUMAB RESPONSE AT THE INDIVIDUAL PATIENT LEVEL OVER TIME IN RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS
https://doi.org/10.1136/annrheumdis-2021-eular.1340
OP0034 IXEKIZUMAB IMPROVES SIGNS, SYMPTOMS, AND QUALITY OF LIFE IN PATIENTS WITH AXIAL SpA IRRESPECTIVE OF DISEASE DURATION: RESULTS FROM THE COAST-V, COAST-W AND COAST-X TRIALS
https://doi.org/10.1136/annrheumdis-2022-eular.164
AB0471 PATIENTS WITH RADIOGRAPHIC axSpA WHO PROGRESSED FROM ASAS20 AT WEEK 16 TO ASAS40 AT WEEK 52: RESULTS FROM COAST-W
https://doi.org/10.1136/annrheumdis-2021-eular.1823
Ixekizumab Improves Signs, Symptoms, and Quality of Life in Patients with Axial Spondyloarthritis Irrespective of Symptom Duration
https://doi.org/10.1007/s12325-025-03305-5
Incidence of infections in patients with psoriatic arthritis and axial spondyloarthritis treated with biological or targeted disease-modifying agents: a systematic review and meta-analysis of randomised controlled trials, open-label studies and observational studies
https://doi.org/10.1136/rmdopen-2023-003064
FRI0421 IXEKIZUMAB SIGNIFICANTLY REDUCED PAIN, INFLAMMATION, AND FATIGUE IN PATIENTS WITH RADIOGRAPHIC AXIAL SPONDYLARTHRITIS (R-AXSPA)/ANKYLOSING SPONDYLITIS (AS)
https://doi.org/10.1136/annrheumdis-2019-eular.1236
Recapture and retreatment rates with ixekizumab after withdrawal of therapy in patients with axial spondyloarthritis: results at week 104 from a randomised placebo-controlled withdrawal study
https://doi.org/10.1136/ard-2022-222731
Documents that mention this clinical trial
POS0926 NORMALIZATION OF HIGH SENSITIVITY CRP VERSUS CLINICAL RESPONSE TO IXEKIZUMAB AT WEEK 16 IN PATIENTS WITH RADIOGRAPHIC & NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: RESULTS FROM THE COAST STUDIES
https://doi.org/10.1136/annrheumdis-2021-eular.2079
THU0395 EFFICACY OF IXEKIZUMAB ON DISEASE ACTIVITY AND QUALITY OF LIFE IN PATIENTS WITH ACTIVE NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS AND OBJECTIVE SIGNS OF INFLAMMATION, STRATIFIED BY BASELINE CRP/SACROILIAC JOINT MRI STATUS
https://doi.org/10.1136/annrheumdis-2020-eular.2027
THU0384 IMPACT OF IXEKIZUMAB ON WORK PRODUCTIVITY IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS PATIENTS: RESULTS FROM THE COAST-X TRIAL AT 52 WEEKS
https://doi.org/10.1136/annrheumdis-2020-eular.2056
Work productivity in patients with axial spondyloarthritis initiating biological or targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review and meta-analysis
https://doi.org/10.1136/rmdopen-2023-003468
Continuing versus withdrawing ixekizumab treatment in patients with axial spondyloarthritis who achieved remission: efficacy and safety results from a placebo-controlled, randomised withdrawal study (COAST-Y)
https://doi.org/10.1136/annrheumdis-2020-219717
Test–retest reliability of outcome measures: data from three trials in radiographic and non-radiographic axial spondyloarthritis
https://doi.org/10.1136/rmdopen-2021-001839
Efficacy and safety of ixekizumab treatment in patients with axial spondyloarthritis: 2-year results from COAST
https://doi.org/10.1136/rmdopen-2021-002165
POS1118 DISCRIMINATING CAPACITY OF THE ASAS HEALTH INDEX IN PATIENTS TREATED WITH IXEKIZUMAB IN THE COAST PROGRAMME
https://doi.org/10.1136/annrheumdis-2023-eular.82
FRI0278 IXEKIZUMAB IMPROVES SELF-REPORTED OVERALL FUNCTIONING AND HEALTH AS MEASURED BY THE ASAS HEALTH INDEX IN PATIENTS WITH NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: 52-WEEK RESULTS OF A PHASE 3 RANDOMIZED, ACTIVE AND PLACEBO-CONTROLLED TRIAL (COAST-X)
https://doi.org/10.1136/annrheumdis-2020-eular.1361
Baseline Characteristics and Treatment Response to Ixekizumab Categorised by Sex in Radiographic and Non-radiographic Axial Spondylarthritis Through 52 Weeks: Data from Three Phase III Randomised Controlled Trials
https://doi.org/10.1007/s12325-022-02132-2
POS0957 EXTERNAL VALIDATION OF THE ALTERNATIVE ANKYLOSING SPONDYLITIS DISEASE ACTIVITY SCORE IN THREE PHASE-3 RCTs
https://doi.org/10.1136/annrheumdis-2022-eular.372
OP0034 IXEKIZUMAB IMPROVES SIGNS, SYMPTOMS, AND QUALITY OF LIFE IN PATIENTS WITH AXIAL SpA IRRESPECTIVE OF DISEASE DURATION: RESULTS FROM THE COAST-V, COAST-W AND COAST-X TRIALS
https://doi.org/10.1136/annrheumdis-2022-eular.164
POS0301 STRUCTURAL OUTCOMES IN THE SACROILIAC JOINT AFTER IXEKIZUMAB TREATMENT FOR 16 WEEKS IN PATIENTS WITH ACTIVE NON‑RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS STRATIFIED BY GENDER, HLA-B27, AND BASELINE MRI INFLAMMATION
https://doi.org/10.1136/annrheumdis-2022-eular.2322
Ixekizumab Improves Signs, Symptoms, and Quality of Life in Patients with Axial Spondyloarthritis Irrespective of Symptom Duration
https://doi.org/10.1007/s12325-025-03305-5
Incidence of infections in patients with psoriatic arthritis and axial spondyloarthritis treated with biological or targeted disease-modifying agents: a systematic review and meta-analysis of randomised controlled trials, open-label studies and observational studies
https://doi.org/10.1136/rmdopen-2023-003064
Recapture and retreatment rates with ixekizumab after withdrawal of therapy in patients with axial spondyloarthritis: results at week 104 from a randomised placebo-controlled withdrawal study
https://doi.org/10.1136/ard-2022-222731
-
Funding
Funding for this research was provided by:
Eli Lilly and Company
- License Information
-
More Information
Article History
Received: 5 May 2025
Accepted: 1 July 2025
First Online: 22 July 2025
Declarations
:
: Victoria Navarro-Compán has served as a speaker, consultant, and/or instructor for AbbVie, Alfasigma, Eli Lilly and Company, Fresenius Kabi, Galapagos, Janssen, Novartis, Pfizer, and UCB Pharma, and has received grant and/or research support from ASAS and Novartis. John D. Reveille has served as a consultant for Eli Lilly and Company and has received grant and/or research support from Eli Lilly and Company. Proton Rahman has served as a speaker and instructor for Abbott, AbbVie, Amgen, Bristol Myers Squibb, Celgene, Eli Lilly and Company, Janssen, Novartis, Pfizer, and UCB Pharma, and has received grant and/or research support from Janssen and Novartis. José A. Maldonado-Cocco has served as a speaker and consultant for and has received grant and/or research support from AbbVie, Bristol Myers Squibb, Gilead Sciences, Merck Sharp & Dohme, Novartis, Pfizer, Roche, Sanofi-Aventis, Schering-Plough, UCB Pharma, and Wyeth. Marina Magrey has served as a speaker and/or consultant for AbbVie, Bristol Myers Squibb, Eli Lilly and Company, Janssen, Novartis, Pfizer, and UCB Pharma. Rebecca Bolce is a former and Tommaso Panni, and Andris Kronbergs are current employees and shareholders of Eli Lilly and Company. Martin Rudwaleit has served as a speaker, consultant, and/or instructor for AbbVie, Boehringer Ingelheim, Bristol Myers Squibb, Chugai Pharmaceutical, Eli Lilly and Company, Janssen, Novartis, Pfizer, and UCB Pharma.
: The trials described herein were conducted in accordance with the ethical principles of the Declaration of Helsinki and were approved by the ethics review boards at each participating study site. The master ethics committee was Schulman Associates IRB, Cincinnati, OH, USA (IRB reference numbers: COAST-V, 201506061; COAST-W, 201506079; COAST-X, 201601302). All patients provided written informed consent prior to participating in the trials.
